VivoSeq
Other

Fibrosis

101

Pipeline Programs↗

27

Active Trials↗

43

Companies Involved↗

Fibrosis is a highly competitive landscape with 101 programs across 43 companies. The most active players are Blade Therapeutics, Bayer, Beijing Continent Pharmaceutical Co, Ltd.. 23 therapies are approved with 18 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

71/100

Pipeline Velocity

27/100

Mech. Concentration

9/100

Completion Rate

80/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

Blade Therapeutics

1 program

Phase 1Bayer logo

Bayer

1 program

Phase 1B

Beijing Continent Pharmaceutical Co, Ltd.

1 program

Phase 2G

Galectin Therapeutics Inc.

1 program

Phase 2T

TaiwanJ Pharmaceuticals Co., Ltd

1 program

Phase 2E

Endeavor Biomedicines, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical16

Losartan

Organon and Co

Colchicine

Alnylam Pharmaceuticals

Efavirenz

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Lopinavir/ritonavir

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Ursodeoxycholic Acid

Daewoong Pharmaceutical Co. LTD.

Phase 16

Gadobutrol

Bayer

Tauroursodeoxycholic Acid

Humanitas Mirasole SpA

BLD-2660

Blade Therapeutics

ND-L02-S0201

Bristol-Myers Squibb

AZD2389

AstraZeneca

Phase 238

Pravastatin

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Semaglutide

Novo Nordisk

GSK2586881

GSK

Pentoxifylline

Validus Pharmaceuticals

Tamoxifen

AstraZeneca

Phase 318

Peginterferon Alfa-2b

Merck & Co.

Obeticholic Acid

Intercept Pharmaceuticals

Pegozafermin

89bio

Imatinib

Novartis

Pirfenidone

Legacy Health System

Approved23

Tocilizumab

Roche

Famotidine

Kenvue Brands

Sirolimus

Prism Pharmaceuticals

Diphenhydramine

Parkedale

Cyclosporine

Novartis

Analysis

Modality Breakdown

93%

Small molecule

99 of 106 classified programs — the dominant modality here.

7%ALL OTHERSMonoclonal antibody33%Protein / enzyme22%Peptide1<1%Cell therapy1<1%

Small molecule leads; the ring shows all 106 classified programs, each share of the total. Modality classified for 100% of 114 pipeline programs.

Analysis

Trial Status

104

clinical trials

Completed40 · 38%
Unknown status27 · 26%
Recruiting16 · 15%
Withdrawn6 · 6%
Active, not recruiting5 · 5%
Not yet recruiting5 · 5%
Other5 · 5%

Clinical Trials

Trial Activity

104 trials

Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06912763·250 enrolled
FAPI PET for Lung Fibrosis
Recruiting·UUniversity of California, Los Angeles·Phase 1·NCT05365802·30 enrolled
Non-Invasive Model for Fibrosis Regression in HBV Patients
Recruiting·—·N/A·NCT06874127·1,100 enrolled
Pirfenidone to Prevent Fibrosis in Ards.
Recruiting·UUniversità Vita-Salute San Raffaele·Phase 3·NCT05075161·130 enrolled
Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD
Recruiting·GGetz Pharma·Phase 4·NCT05644717·164 enrolled
Fibrosis Lessens After Metabolic Surgery
Recruiting·—·Phase 4·NCT06374875·120 enrolled
Early Discontinuation of Steroid Treatment in Negative FDG-PET/CT Patients With Idiopathic Retroperitoneal Fibrosis
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 4·NCT05428826·41 enrolled
Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis
Recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 2·NCT06913647·30 enrolled
Effect of Some Drugs on Liver Fibrosis
Recruiting·—·Phase 3·NCT03770936·45 enrolled
Study of Sirolimus in Idiopathic Retroperitoneal Fibrosis
Recruiting·PPeking University International Hospital·Phase 2/3·NCT04047576·60 enrolled
Losartan for Corneal Fibrosis
Recruiting·UUniversidad Autonoma de Nuevo Leon·N/A·NCT07449000·46 enrolled
Efficacy of Simvastatin in Alcoholic Liver Fibrosis
Recruiting·—·Phase 2/3·NCT04971577·90 enrolled
FAPI-74 PET/CT in Adults With Fibrosis
Recruiting·—·Phase 1·NCT06413355·45 enrolled
Study of the Efficacy and Safety of Nicotinamide in Patients With Liver Fibrosis (NICOFIB)
Recruiting·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau·Phase 2·NCT06599918·30 enrolled
Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis
Recruiting·UUniversity of Nebraska·Phase 4·NCT02842424·70 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)